Pipoxolan

Pipoxolan hydrochloride emerged in clinical practice as a novel surgical adjuvant — what has commonly been termed a "muscle relaxant" in Chinese medical literature. Its introduction fundamentally changed the practice of anesthesiology: by providing muscle relaxation under relatively light anesthesia, Pipoxolan eliminated the need to deepen general anesthesia solely for the purpose of achieving muscular flaccidity during surgery. This represented a meaningful advance in patient safety at the time.

However, the pharmacology of Pipoxolan extends far beyond surgical relaxation. It is formally classified as an antispasmodic agent, exerting its primary therapeutic effect by relieving smooth muscle spasms in the digestive tract, gallbladder, urogenital system, and in the management of menstrual cramps. In recent years, a growing body of research has revealed entirely new dimensions of Pipoxolan's biological activity, including the induction of apoptosis, elevation of intracellular reactive oxygen species (ROS), and down‑regulation of matrix metalloproteinases MMP‑2 and MMP‑9. These properties have positioned Pipoxolan as a compound of interest in oncology research, with demonstrated preclinical activity against leukemia, oral squamous cell carcinoma, and lung adenocarcinoma.

Product Parameters

Clinical Applications — From Surgical Suite to Modern Therapeutics

1. Surgical Muscle Relaxation (Historical Context)

Pipoxolan hydrochloride was introduced as a novel surgical adjunct — commonly referred to as a muscle relaxant — that fundamentally changed the approach to achieving muscular flaccidity during surgical procedures. Prior to its availability, surgeons often relied on deepening general anesthesia to achieve the necessary degree of muscle relaxation, a practice that carried increased risk of respiratory depression, cardiovascular instability, and prolonged recovery times. By providing muscle relaxation under comparatively light anesthesia, pipoxolan hydrochloride allowed anesthesiologists to maintain patients at a shallower plane of anesthesia while still providing the surgeon with adequate operating conditions. This represented a significant advance in patient safety and recovery.

2. Antispasmodic Indications

The formal therapeutic category of pipoxolan hydrochloride is that of an antispasmodic agent. It acts by directly relaxing smooth muscle, relieving spasms in three major systems of the body.By reducing smooth muscle hypertonicity without affecting normal peristalsis, pipoxolan hydrochloride provides symptomatic relief while allowing the underlying condition to be addressed.

3. Emerging Anticancer Research

Modern pharmacology has revealed that pipoxolan hydrochloride does more than relax smooth muscle. Preclinical studies demonstrate that it induces apoptosis and increases intracellular reactive oxygen species (ROS), two hallmarks of anticancer activity. Mechanistically, the compound down‑regulates the phosphorylation of JNK and p38 signaling proteins, leading to reduced expression of MMP‑2 and MMP‑9 — matrix metalloproteinases that are critical for tumor invasion and metastasis.While these findings remain at the preclinical stage, they have positioned pipoxolan hydrochloride as a compound of interest in oncology research programs investigating the repurposing of existing drugs for new therapeutic indications.

Manufacturing Process and Quality Control at Cosperpharm

1. Synthetic Route Overview

The synthesis of pipoxolan hydrochloride proceeds through a well‑established route, first described by M. Pailer and colleagues (Monatsh. Chem. 99, 891, 1968) and subsequently protected by patents (GB 1109959 and BE 719230, both assigned to Rowa‑Wagner). The key steps involve the condensation of a piperidine‑containing side chain with a diphenyl‑substituted dioxolanone core, followed by salt formation with hydrogen chloride. Cosperpharm has optimized this route for scalability, employing solvent‑minimized procedures that avoid chromatographic purification for commercial batches.

2. Quality Control Testing

Each batch of CAS 18174‑58‑8 undergoes a comprehensive testing protocol:

● HPLC purity — ≥98.0% area, using a validated method with UV detection

● Melting point — 207–209 °C (sharp range confirms crystalline purity)

● ¹H NMR — Confirmatory analysis of the diphenyl, piperidine, and dioxolanone moieties

● LC‑MS — Confirmation of molecular weight ([M+H]⁺ expected 388.2)

● Loss on drying — ≤0.5%

● Residual solvents — GC analysis for IPA, ethyl acetate, and other process solvents

● Heavy metals — Pharmacopoeia limits (available upon request)

● Appearance — White to off‑white crystalline powder, no visible particles

A complete Certificate of Analysis (COA), Material Safety Data Sheet (MSDS), and Certificate of Origin accompany every shipment. For regulatory submissions, stability data and method validation reports are available upon request.

Contact Cosperpharm — Get Your Pipoxolan Hydrochloride Today

Ready to incorporate pipoxolan hydrochloride (CAS 18174‑58‑8) into your antispasmodic research, oncology screening program, or pharmaceutical development project? Cosperpharm supplies this versatile compound with consistent purity, full documentation, and flexible packaging to meet your needs — from research quantities to pilot‑scale lots.